- Report
- January 2024
- 92 Pages
From €3275EUR$3,450USD£2,763GBP
- Report
- January 2024
- 241 Pages
Global
From €4225EUR$4,450USD£3,563GBP
- Report
- September 2023
- 216 Pages
Global
From €4225EUR$4,450USD£3,563GBP
From €3275EUR$3,450USD£2,763GBP
- Report
- January 2024
- 112 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- September 2023
- 115 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- January 2025
- 132 Pages
Global
From €902EUR$950USD£761GBP
- Report
- April 2024
- 132 Pages
Global
From €902EUR$950USD£761GBP
Cell and Gene Therapy Manufacturing is a rapidly growing field within the genomics industry. It involves the production of therapeutic cells and genes for use in medical treatments. This includes the production of stem cells, gene-modified cells, and gene-editing tools. The process involves the isolation, expansion, and differentiation of cells, as well as the production of gene-editing tools such as CRISPR-Cas9. The goal is to create therapeutic cells and genes that can be used to treat a variety of diseases.
Cell and Gene Therapy Manufacturing is a highly specialized field, requiring expertise in cell biology, molecular biology, and biochemistry. It also requires the use of advanced technologies such as gene-editing tools, cell culture systems, and bioreactors.
Companies in the Cell and Gene Therapy Manufacturing market include bluebird bio, Cellectis, CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics. These companies are focused on developing and manufacturing therapeutic cells and genes for use in medical treatments. Show Less Read more